Rylaze
Rylaze ingredients
| Active ingredient | Strength |
|---|---|
| Asparaginase | 20 mg/mL |
What Rylaze is used for
The FDA lists the approved uses on the official label (below). In the EU, asparaginase is approved as Spectrila for:
Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Rylaze
- Generic name
- Asparaginase erwinia chrysanthemi (recombinant)-rywn
- Made by
- Jazz Pharmaceuticals, Inc.
- Forms
- Injection
- Given
- Intramuscular
- Drug class
- Asparagine-specific Enzyme
- FDA approval
- Biologic licence (BLA) BLA761179
- On the US market since
- 2021
Official information
- Rylaze prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Asparaginase erwinia chrysanthemi (recombinant)-rywn)
In India
- Asparaginase: 28 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rylaze?
Rylaze (Asparaginase erwinia chrysanthemi (recombinant)-rywn) is a cancer medicine made by Jazz Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Rylaze?
Rylaze contains Asparaginase (20 mg/mL).
Is Rylaze approved in Europe?
The same active substance is approved in the EU as Spectrila.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA